- Home
- PAVM vs CYCC Comparison
PAVM vs CYCC Comparison
Compare PAVM & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- CYCC
- Stock Information
- Founded
- PAVM 2014
- CYCC 1992
- Country
- PAVM United States
- CYCC Malaysia
- Employees
- PAVM N/A
- CYCC N/A
- Industry
- PAVM Medical/Dental Instruments
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- CYCC Health Care
- Exchange
- PAVM Nasdaq
- CYCC Nasdaq
- Market Cap
- PAVM 8.0M
- CYCC 7.8M
- IPO Year
- PAVM 2016
- CYCC N/A
- Fundamental
- Price
- PAVM $0.46
- CYCC $8.90
- Analyst Decision
- PAVM Strong Buy
- CYCC
- Analyst Count
- PAVM 1
- CYCC 0
- Target Price
- PAVM $19.00
- CYCC N/A
- AVG Volume (30 Days)
- PAVM 250.8K
- CYCC 1.9M
- Earning Date
- PAVM 08-14-2025
- CYCC 08-13-2025
- Dividend Yield
- PAVM N/A
- CYCC N/A
- EPS Growth
- PAVM N/A
- CYCC N/A
- EPS
- PAVM 0.96
- CYCC N/A
- Revenue
- PAVM $1,993,000.00
- CYCC $14,000.00
- Revenue This Year
- PAVM N/A
- CYCC $137.21
- Revenue Next Year
- PAVM $455.63
- CYCC N/A
- P/E Ratio
- PAVM $0.48
- CYCC N/A
- Revenue Growth
- PAVM N/A
- CYCC N/A
- 52 Week Low
- PAVM $0.30
- CYCC $3.08
- 52 Week High
- PAVM $1.90
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- PAVM 35.35
- CYCC 45.78
- Support Level
- PAVM $0.43
- CYCC $8.67
- Resistance Level
- PAVM $0.53
- CYCC $10.08
- Average True Range (ATR)
- PAVM 0.05
- CYCC 1.51
- MACD
- PAVM -0.01
- CYCC -0.19
- Stochastic Oscillator
- PAVM 52.70
- CYCC 15.66
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.